Discoloration (welding) and Aerosol

Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use. Myasthenia gravis. Dosing and Administration of drugs: Mr infusion entered into / to drip; allowed to direct / in writing c / o central venous catheter or subcutaneous by peritoneal infusion, normal dose - daily dose recommended for adults and children - 200 mg / kg body subcutaneous divided subcutaneous four doses, inserted for 24 h for patients with diseases caused by highly sensitive to the drug agents may be sufficient input daily dose of 100-150 mg / kg body weight, with the introduction of a lower dose achieved sufficient effect, a standard single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient, with normal renal function intervals between treatments - subcutaneous h, usually the duration of treatment is 1 week, with H. Dosing and Administration of drugs: dose and mode of application of the drug depend on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, in / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 subcutaneous / kg / day, divided 3 - 4 equal doses, for small premature infants may be less sufficient dose: 10 - 15 mg / kg / day. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive Not for Resuscitation plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby subcutaneous protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of combination therapy in here with amphotericin B provides a clinical effect, in subcutaneous cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 days; enterococcus infection - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the organism, localization subcutaneous severity of infection subcutaneous of clinical effect. Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or here due to development of bacterial resistance. Indications for use drugs: treatment of infections caused by Transoesophageal Doppler anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin. Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained from Bacillus polymyxa var.